Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 24
1993 127
1994 203
1995 288
1996 347
1997 468
1998 372
1999 476
2000 548
2001 659
2002 713
2003 718
2004 629
2005 781
2006 881
2007 882
2008 858
2009 869
2010 925
2011 978
2012 1038
2013 1011
2014 949
2015 1068
2016 966
2017 940
2018 914
2019 949
2020 910
2021 778
2022 630
2023 514
2024 757
2025 765
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,562 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. Shitara K, et al. N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119. Epub 2025 May 31. N Engl J Med. 2025. PMID: 40454632 Clinical Trial.
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Olawaiye AB, et al. Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2. Lancet. 2025. PMID: 40473448 Clinical Trial.
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
Rao S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, Morano F, Roy A, Dahan L, Tamberi S, Dhadda AS, Saunders MP, Casanova N, Guimbaud R, Lievre A, Maurel J, Fakih M, Tian C, Harrison J, Jones MM, Cornfeld M, Spano JP, Rochefort P; POD1UM-303/InterAACT-2 study investigators. Rao S, et al. Lancet. 2025 Jun 14;405(10495):2144-2152. doi: 10.1016/S0140-6736(25)00631-2. Lancet. 2025. PMID: 40517007 Free article. Clinical Trial.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.
Babiker HM, Picozzi V, Chandana SR, Melichar B, Kasi A, Gang J, Gallego J, Bullock A, Chunyi H, Wyrwicz L, Hitre E, Osipov A, de la Fouchardiere C, Ales I, Dragovich T, Lee W, Feeney K, Philip P, Ueno M, Van Cutsem E, Seufferlein T, Macarulla T; PANOVA-3 Study Investigators. Babiker HM, et al. J Clin Oncol. 2025 Jul 20;43(21):2350-2360. doi: 10.1200/JCO-25-00746. Epub 2025 May 31. J Clin Oncol. 2025. PMID: 40448572 Clinical Trial.
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Ohba A, Ozaka M, Mizusawa J, Okusaka T, Kobayashi S, Yamashita T, Ikeda M, Yasuda I, Sugimori K, Sasahira N, Ikezawa K, Miki I, Okano N, Mizuno N, Furukawa M, Shirakawa H, Sano Y, Katayama H, Furuse J, Ueno M; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Ohba A, et al. J Clin Oncol. 2025 Nov;43(31):3345-3354. doi: 10.1200/JCO.24.00936. Epub 2025 Jul 28. J Clin Oncol. 2025. PMID: 40720715 Free PMC article. Clinical Trial.
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.
Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, Imai Y, Kondo E, Takehara K, Takano H, Kudaka W, Kado N, Yamagami W, Kato H, Nishino K, Usami T, Hamanishi J, Nii M, Takaya I, Okamoto A. Nishio S, et al. J Gynecol Oncol. 2025 Jul;36(4):e118. doi: 10.3802/jgo.2025.36.e118. J Gynecol Oncol. 2025. PMID: 40590327 Free PMC article. Clinical Trial.
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
Cortés J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM; ASCENT-03 Clinical Trial Investigators. Cortés J, et al. N Engl J Med. 2025 Nov 13;393(19):1912-1925. doi: 10.1056/NEJMoa2511734. Epub 2025 Oct 19. N Engl J Med. 2025. PMID: 41124233 Clinical Trial.
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).
Shiraishi Y, Shimose T, Tobino K, Toi Y, Wakuda K, Matsumoto H, Sakaguchi T, Mashimoto A, Hayashi H, Ebina-Shibuya R, Mori M, Taniguchi Y, Kuyama S, Kashiwabara K, Furuyama K, Yoshimine K, Kimura Y, Kobayashi H, Kishimoto J, Okamoto I. Shiraishi Y, et al. Lung Cancer. 2025 May;203:108543. doi: 10.1016/j.lungcan.2025.108543. Epub 2025 Apr 18. Lung Cancer. 2025. PMID: 40253945 Free article. Clinical Trial.
GCN2 regulates paclitaxel-induced neuropathic pain.
Mikesell AR, Meyer AR, García G, Frietze LR, Stucky CL, Pan T, Campbell ZT. Mikesell AR, et al. Br J Pharmacol. 2025 Dec;182(23):5913-5930. doi: 10.1111/bph.70154. Epub 2025 Aug 13. Br J Pharmacol. 2025. PMID: 40803344
Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.
Liu Z, Wang D, Li G, Yi M, Zhang Z, Zhong G, Xu L, Jiang R, Zheng Y, Huang L, Peng Y, Liang L, Li J, Liu Y, Lai J, Lv X, Xu Y, Liu Q, Wang Z, Liu Z, Yang Q, Nie L, Lei J, Huang X, Liu Z, Jiang W. Liu Z, et al. Nat Commun. 2025 May 17;16(1):4608. doi: 10.1038/s41467-025-59865-1. Nat Commun. 2025. PMID: 40382318 Free PMC article. Clinical Trial.
21,562 results
You have reached the last available page of results. Please see the User Guide for more information.